Etzer Darout

Stock Analyst at Barclays

(3.30)
# 1,047
Out of 5,044 analysts
132
Total ratings
43.81%
Success rate
4.5%
Average return

Stocks Rated by Etzer Darout

Terns Pharmaceuticals
Oct 22, 2025
Maintains: Overweight
Price Target: $15$14
Current: $8.59
Upside: +62.98%
Summit Therapeutics
Oct 21, 2025
Maintains: Underweight
Price Target: $13$16
Current: $19.23
Upside: -16.80%
RAPT Therapeutics
Oct 21, 2025
Maintains: Overweight
Price Target: $35$58
Current: $30.13
Upside: +92.50%
CytomX Therapeutics
Oct 21, 2025
Maintains: Overweight
Price Target: $3.5$6
Current: $3.32
Upside: +80.72%
Celldex Therapeutics
Oct 13, 2025
Initiates: Underweight
Price Target: $25
Current: $27.06
Upside: -7.61%
Tvardi Therapeutics
Oct 13, 2025
Initiates: Overweight
Price Target: $61
Current: $4.72
Upside: +1,192.37%
Oruka Therapeutics
Oct 13, 2025
Initiates: Overweight
Price Target: $48
Current: $27.44
Upside: +74.93%
Monopar Therapeutics
Oct 13, 2025
Initiates: Overweight
Price Target: $125
Current: $79.92
Upside: +56.41%
Corvus Pharmaceuticals
Oct 13, 2025
Initiates: Overweight
Price Target: $16
Current: $7.59
Upside: +110.80%
AnaptysBio
Oct 13, 2025
Initiates: Overweight
Price Target: $78
Current: $36.16
Upside: +115.71%
Initiates: Overweight
Price Target: $142
Current: $94.25
Upside: +50.67%
Downgrades: Equal-Weight
Price Target: $112$97
Current: $94.89
Upside: +2.22%
Maintains: Overweight
Price Target: $45$44
Current: $29.88
Upside: +47.26%
Maintains: Overweight
Price Target: $8$10
Current: $2.58
Upside: +287.60%
Assumes: Underweight
Price Target: $6
Current: $14.25
Upside: -57.89%
Assumes: Overweight
Price Target: $3
Current: $1.85
Upside: +62.16%
Initiates: Equal-Weight
Price Target: $40
Current: $40.08
Upside: -0.19%
Assumes: Overweight
Price Target: $16
Current: $9.50
Upside: +68.42%
Initiates: Overweight
Price Target: $72
Current: $78.51
Upside: -8.29%
Initiates: Overweight
Price Target: $60
Current: $61.95
Upside: -3.15%
Initiates: Overweight
Price Target: $47
Current: $29.76
Upside: +57.93%
Maintains: Buy
Price Target: $9$13
Current: $5.27
Upside: +146.68%
Maintains: Outperform
Price Target: $130$143
Current: $105.03
Upside: +36.15%
Downgrades: Market Perform
Price Target: $22$3
Current: $2.56
Upside: +17.19%
Initiates: Outperform
Price Target: $50
Current: $47.98
Upside: +4.21%
Initiates: Outperform
Price Target: $35
Current: $11.90
Upside: +194.12%
Initiates: Outperform
Price Target: $63
Current: $2.34
Upside: +2,592.31%
Maintains: Outperform
Price Target: $28$27
Current: $1.98
Upside: +1,263.64%
Maintains: Outperform
Price Target: $132$134
Current: $101.22
Upside: +32.38%
Reiterates: Outperform
Price Target: $46$48
Current: $29.13
Upside: +64.78%
Maintains: Market Perform
Price Target: $118$120
Current: $123.43
Upside: -2.78%
Maintains: Market Perform
Price Target: $7$6
Current: $1.49
Upside: +302.68%
Maintains: Outperform
Price Target: $80$82
Current: $82.61
Upside: -0.74%
Maintains: Outperform
Price Target: $20$19
Current: $4.45
Upside: +326.97%
Upgrades: Buy
Price Target: $170
Current: $475.91
Upside: -64.28%
Initiates: Buy
Price Target: $54
Current: $54.00
Upside: -
Maintains: Buy
Price Target: $27$38
Current: $70.51
Upside: -46.11%
Maintains: Outperform
Price Target: $54$52
Current: $2.39
Upside: +2,075.73%